Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04262141 | IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) | PHASE2 | ACTIVE NOT_RECRUITING | 4 | — | — | Oct 2, 2020 | Oct 31, 2027 | Jan 7, 2026 | 1 | United States |
As evaluated by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Leukemia Net (ELN) response criteria.
| Arm | Type | Description |
|---|---|---|
| IMG-7289 in ET and PV Patients | EXPERIMENTAL | Oral daily dose of 0.6 mg/kg/day IMG-7289 will be administered: * The initial pilot period will enroll 8 participants to receive oral daily dose of IMG-7829 for 24 weeks, iteratively as long as there is clinical benefit in the absence of excess toxicity. * The second stage group will enroll an additional 16 participants to receive IMG-7829 for over 2 years, iteratively as long as there is clinical benefit in the absence of toxicity. |
| Name | Type | Description |
|---|---|---|
| IMG-7289 | DRUG | Daily oral dose of 0.6 mg/kg/day IMG-7829 capsules. Dose escalation an de-escalation rules applied as necessary. |
Inclusion Criteria: 1. Age ≥ 18 years. 2. Diagnosis of Essential Thrombocythemia or Polycythemia Vera per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms (Arber et al., 2016). 3. Patients that have failed at least one standard therapy (failure is the equivalent ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE3 | Bomedemstat, Hydroxyurea, Anagrelide, Busulfan, Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b |
| Incyte Corporation | INCY | 1 | PHASE1 | INCB057643, Ruxolitinib |